Synopsis:
Advanced Enzyme Tech’s subsidiary approves collaboration with Raywatt Solar to set up a group captive solar power plant via SPV, investing 26 percent equity to meet its plant’s energy needs sustainably and cost-effectively.
During Monday’s trading session, shares of a research-centric company holding a global leadership position in enzymes & probiotics manufacturing surged nearly 7.3 percent on BSE, after its subsidiary’s Board approved a collaboration with Raywatt Solar for setting up a solar power plant.
At 10:49 a.m., shares of Advanced Enzyme Technologies Limited were trading in the green at Rs. 345.15 on BSE, up by nearly 6 percent, as against its previous closing price of Rs. 326.35, with a market cap of Rs. 3,861 crores. The stock has delivered negative returns of more than 18 percent in the last one year, but has gained by about 7 percent in the last one month.
What’s the News
According to recent regulatory filings, Advanced Enzyme Technologies Limited has informed that the Board of JC Biotech Private Limited (a 95.72 percent subsidiary) has approved a collaboration with Raywatt Solar Power Systems Private Limited for the development of a group captive solar power project.
The project will be implemented through a Special Purpose Vehicle (SPV), in which JC Biotech is required to invest 26 percent equity as per applicable legal provisions. This SPV will be responsible for setting up the solar power plant to meet the power/electricity requirements through solar for JC Biotech’s plant located at APIIC Growth Centre, Gundlapalli Village, Ongole, Andhra Pradesh.
The total investment in the SPV is expected to be up to Rs. 10 million, with the acquisition targeted for completion by 31st March 2026. This initiative aims to meet JC Biotech’s power requirements through sustainable and cost-effective solar energy over the long term.
Financials & more
Advanced Enzyme Tech reported a marginal growth in its revenue from operations, showing a year-on-year rise of around 6 percent from Rs. 158 crores in Q4 FY24 to Rs. 167 crores in Q4 FY25.
In contrast, its net profit decreased during the same period from Rs. 30 crores to Rs. 27 crores, representing a decline of about 10 percent YoY. The financial results for Q1 FY26 will be announced on 2nd August 2025.
Advanced Enzyme Technologies Limited is a research-centric company engaged in the business of manufacturing and selling enzymes. It is the largest Indian enzymes & probiotics company engaged in research and development, manufacturing and marketing of 400+ proprietary products developed from over 65 indigenous enzymes and probiotics.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
